Exact Mass: 618.3199
Exact Mass Matches: 618.3199
Found 266 metabolites which its exact mass value is equals to given mass value 618.3199
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Minosaminomycin
Z-Ile-Glu(O-t-butyl)-Ala-Leucinal
D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D015853 - Cysteine Proteinase Inhibitors
PI(20:5(5Z,8Z,11Z,14Z,17Z)/0:0)
PA(8:0/20:3(8Z,11Z,14Z)-2OH(5,6))
PA(8:0/20:3(8Z,11Z,14Z)-2OH(5,6)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/20:3(8Z,11Z,14Z)-2OH(5,6)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 5,6-dihydroxyeicosatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(20:3(8Z,11Z,14Z)-2OH(5,6)/8:0)
PA(20:3(8Z,11Z,14Z)-2OH(5,6)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(8Z,11Z,14Z)-2OH(5,6)/8:0), in particular, consists of one chain of one 5,6-dihydroxyeicosatrienoyl at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
23-Ketone,3,28-disulfate-Cycloartane-3,23,28-triol
Petuniasterone B 22-O-<(methylthio)-carbonyl>acetate < (22R,24S)-1alpha-acetoxy-24,25-epoxy-7alpha-hydroxy-22-(methylthiocarbonyl)acetoxyoergost-4-en-3-one >|Petuniasterone B 22-O-[(methylthio)-carbonyl]acetate [ (22R,24S)-1alpha-acetoxy-24,25-epoxy-7alpha-hydroxy-22-(methylthiocarbonyl)acetoxyoergost-4-en-3-one ]
(2R,3R,4S,5R,7S,8R,13R,15R)-3,5,7,15-tetraacetoxy-8-isobutyroyloxy-9,14-dioxo-jatropha-6(17),11E-diene
(1S,5S,7R)-3-(3,4-dihydroxybenzoyl)-4-hydroxy-5-[(E)-4-hydroxy-3,7-dimethylocta-2,6-dienyl]-8,8-dimethyl-1,7-bis(3-methylbut-2-enyl)bicyclo[3.3.1]non-3-ene-2,9-dione|32-hydroxy-ent-guttiferone M
1-O-cinnamoyl-17-defurano-17-(2-buten-4-olide-2-yl)salannic acid methyl ester|ohchininolide
4-acetoxy-1beta-(2-methylbutyryloxy)-14-desacetoxy-3,14-dehydro-8,10-epoxyabrotanifolone
(21alpha)-21-hydroxythyrsiferol|(alpha(2)S,2R,4S,5R)-;alpha;(2)-{(3S)-3-{(2R,4aR,6R,8aS)-6-[(2S,5R)-5-bromotetrahydro-2,6,6-trimethyl-2H-pyran-2-yl]octahydro-8a-methylpyrano[3,2-b]pyran-2-yl}-3-hydroxybutyl}tetrahydro-4-hydroxy-alpha(5),alpha(5),2-trimethylfuran-2,5-dimethanol
11-benzoyl-14-([E]-3,7-dimethyl-2,6-octadienyl)-3-(1-hydroxy-1-methylethyl)-6,6,10,10-tetramethyl-4,5-dioxatetracyclo[7,3,3,1(11,14)0(1,7)]hexadecane-12,13,16-trione|otogirinin B
[9-[(E)-3-acetyloxy-4-methylhex-4-en-2-yl]-12-hydroxy-3-(2-hydroxypropan-2-yl)-10-methoxy-6a,12b-dimethyl-8,11-dioxo-1,2,3,4a,5,6,12,12a-octahydropyrano[3,2-a]xanthen-1-yl] acetate
Asp Ile Trp Trp
Asp Leu Trp Trp
Asp Trp Ile Trp
Asp Trp Leu Trp
Asp Trp Trp Ile
Asp Trp Trp Leu
Glu Glu Arg Trp
Glu Glu Trp Arg
Glu Arg Glu Trp
Glu Arg Trp Glu
Glu Val Trp Trp
Glu Trp Glu Arg
Glu Trp Arg Glu
Glu Trp Val Trp
Glu Trp Trp Val
Ile Asp Trp Trp
Ile Trp Asp Trp
Ile Trp Trp Asp
Leu Asp Trp Trp
Leu Trp Asp Trp
Leu Trp Trp Asp
Arg Glu Glu Trp
Arg Glu Trp Glu
Arg Trp Glu Glu
Val Glu Trp Trp
Val Trp Glu Trp
Val Trp Trp Glu
Trp Asp Ile Trp
Trp Asp Leu Trp
Trp Asp Trp Ile
Trp Asp Trp Leu
Trp Glu Glu Arg
Trp Glu Arg Glu
Trp Glu Val Trp
Trp Glu Trp Val
Trp Ile Asp Trp
Trp Ile Trp Asp
Trp Leu Asp Trp
Trp Leu Trp Asp
Trp Arg Glu Glu
Trp Val Glu Trp
Trp Val Trp Glu
Trp Trp Asp Ile
Trp Trp Asp Leu
Trp Trp Glu Val
Trp Trp Ile Asp
Trp Trp Leu Asp
Trp Trp Val Glu
PI(20:5(5Z,8Z,11Z,14Z,17Z)/0:0)
desferrioxamine G
2,2-DI(4-TERT-OCTYLPHENYL)-1-PICRYL-HYDRAZYL, FREE RADICAL
tris(2,2,6,6-tetramethyl-3,5-heptanedionato)gallium(iii)
(E)-(S)-4-[(S)-4-Methyl-2-((S)-3-methyl-2{(S)-2-[(5-methyl-isoxazole-3-carbonyl)-amino]-propionylamino}-butyrylamino)-pentanoylamino]-5-((S)-2-oxo-pyrrolidin-3-YL)-pent-2-enoic acid ethyl ester
[2-hydroxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropyl] (5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoate
2-[[(2R)-3-acetyloxy-2-[(5R,6Z,8E,10E,12S,14Z)-5,12-dihydroxyicosa-6,8,10,14-tetraenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(2R)-2-acetyloxy-3-[(5S,6Z,8E,10E,12R,14Z)-5,12-dihydroxyicosa-6,8,10,14-tetraenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(2R)-3-acetyloxy-2-[(5S,6E,8Z,11Z,13E,15R)-5,15-dihydroxyicosa-6,8,11,13-tetraenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(2R)-2-acetyloxy-3-[(5R,6E,8Z,11Z,13E,15S)-5,15-dihydroxyicosa-6,8,11,13-tetraenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(2R)-3-acetyloxy-2-[(5R,6R,8Z,11Z,14Z,17Z)-5,6-dihydroxyicosa-8,11,14,17-tetraenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(2R)-2-acetyloxy-3-[(5S,6S,8Z,11Z,14Z,17Z)-5,6-dihydroxyicosa-8,11,14,17-tetraenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
32-Hydroxy-ent-guttiferone M
A natural product found in Rheedia edulis.
6beta-acetoxy-3beta-(beta-D-glucopyranosyloxy)-8alpha,14-dihydroxybufa-4,20,22-trienolide
(4R,7R,8S)-14-(cyclohexanecarbonylamino)-8-methoxy-4,7,10-trimethyl-11-oxo-N-[4-(trifluoromethyl)phenyl]-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-triene-5-carboxamide
S-[2-[3-[[(2R)-2-hydroxy-3,3-dimethyl-4-phosphonooxybutanoyl]amino]propanoylamino]ethyl] (9Z,12Z,15Z)-octadeca-9,12,15-trienethioate
[2-hydroxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropyl] (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate
2-(3-((Z)-3-Tributylstannyl-1-propenoxy)-(2R,3S,5AR,6AS,10AR,12AS)-tetrahydropyrano(3,2-B)oxepano(2,3:6,7)oxepan-2-YL)ethanal
[9-[(E)-3-acetyloxy-4-methylhex-4-en-2-yl]-12-hydroxy-3-(2-hydroxypropan-2-yl)-10-methoxy-6a,12b-dimethyl-8,11-dioxo-1,2,3,4a,5,6,12,12a-octahydropyrano[3,2-a]xanthen-1-yl] acetate
[1-hydroxy-3-[hydroxy-(3-hydroxy-2-pentanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (11Z,14Z,17Z)-icosa-11,14,17-trienoate
[1-[(2-heptanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate
[1-hydroxy-3-[hydroxy-(3-hydroxy-2-nonanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate
[1-hydroxy-3-[hydroxy-(3-hydroxy-2-propanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (10Z,13Z,16Z)-docosa-10,13,16-trienoate
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-heptanoyloxypropan-2-yl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-propanoyloxypropan-2-yl] (10Z,13Z,16Z)-docosa-10,13,16-trienoate
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-nonanoyloxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-pentanoyloxypropan-2-yl] (11Z,14Z,17Z)-icosa-11,14,17-trienoate
[1-[(6E,9E,12E)-pentadeca-6,9,12-trienoyl]oxy-3-phosphonooxypropan-2-yl] (5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoate
(2S)-2-[[(2S)-3-[(4R)-2-amino-4,5-dihydro-1H-imidazol-4-yl]-1-[[(2S,3S,5R,6S)-4-[(2R,3S,5S,6R)-3,5-diamino-6-methyloxan-2-yl]oxy-2,3,5,6-tetrahydroxycyclohexyl]amino]-1-oxopropan-2-yl]carbamoylamino]-4-methylpentanoic acid
PAR-4 (1-6) amide (human)
PAR-4 (1-6) amide human is an N-terminal fragment of protease-activated receptor 4 (PAR4). PAR-4 (1-6) amide human induce platelet aggregation[1].